<bill session="116" type="h" number="1362" updated="2019-06-27T10:56:13Z">
  <state datetime="2019-02-26">REFERRED</state>
  <status>
    <introduced datetime="2019-02-26"/>
  </status>
  <introduced datetime="2019-02-26"/>
  <titles>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to allow, during a lapse in appropriations, acceptance of certain device submissions and registrations with the corresponding fees made available for obligation and expenditure for the process for the review of device applications, and for other purposes.</title>
    <title type="short" as="introduced">Medical Innovation Never Stops Act of 2019</title>
    <title type="short" as="introduced">Medical Innovation Never Stops Act of 2019</title>
    <title type="display">Medical Innovation Never Stops Act of 2019</title>
  </titles>
  <sponsor bioguide_id="E000294"/>
  <cosponsors/>
  <actions>
    <action datetime="2019-02-26">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-02-26" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Appropriations"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Executive agency funding and structure"/>
    <term name="Licensing and registrations"/>
    <term name="User charges and fees"/>
  </subjects>
  <amendments/>
  <committee-reports/>
</bill>
